Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 53Neoplasms 44Prostatic Neoplasms 43Breast Neoplasms 38Neoplasm Metastasis 21Unspecified Adult Solid Tumor, Protocol Specific 19Lung Neoplasms 18Head and Neck Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Ovarian Neoplasms 15Advanced Solid Tumors 11Stomach Neoplasms 9Sarcoma 9Pancreatic Neoplasms 9Solid Tumor 8Melanoma 8Esophageal Neoplasms 8Carcinoma, Ovarian Epithelial 8Urinary Bladder Neoplasms 7Fallopian Tube Neoplasms 7Colorectal Neoplasms 7Small Cell Lung Carcinoma 6Salivary Gland Neoplasms 6Esthesioneuroblastoma, Olfactory 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Renal Cell 5Breast Neoplasms, Male 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4

Interventions

Paclitaxel 8Carboplatin 8Taxes 6Topotecan 3Cisplatin 3Bevacizumab 3SS1(dsFv)PE38 2Filgrastim 2Etoposide 2veliparib 1trioctyl phosphine oxide 1paclitaxel poliglumex 1VTX-2337 1Thiotepa 1Reverse Transcriptase Polymerase Chain Reaction 1Platinum 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Docetaxel 1Disulfides 1Chemotherapy, Adjuvant 1Bortezomib 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brenner Tumor × Docetaxel × Clear all
NCT00085358 2019-07-22

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡